Page last updated: 20 December 2024
Current Reviews
Current Post-market Reviews
- There are no current Post-market Reviews.
What are Post-Market Reviews of PBS listed Medicines?
Completed Post-market Reviews
- Opiate Dependence Treatment Program
- Medicines for smoking cessation
- The use of biologics in the treatment of severe chronic plaque psoriasis
- Pulmonary Arterial Hypertension (PAH) Medicines
- Chronic Obstructive Pulmonary Disease (COPD) Medicines
- Ezetimibe
- Alzheimers Disease medicines
- Anticoagulation Therapies in Atrial Fibrillation
- Asthma in Children
- Diabetes
Completed Other Reviews
- Utilisation analysis of PBS-listed heart failure medicines
- PBS restrictions for ezetimibe and its fixed dose combinations
- PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines
- Stocktake of PBS medicines available for endometriosis and related conditions, and comparison of current Australian pharmacological treatment guidelines (2022)
- Pharmaceutical Reform Agreement (PRA) Review Report
- Review of cancer related surrogate outcomes used for Pharmaceutical Benefits Advisory Committee (PBAC) decision making
- Efficient Funding of Chemotherapy Review
- Overall survival in people receiving PBS-listed cancer medicines in Australian clinical practice
- PBS Pharmaceuticals in Hospitals Review
- Review of Pharmacy Remuneration and Regulation
- Authority Required PBS Listings
- Life Saving Drugs Program
- Pharmaceutical Benefits Advisory Committee Guidelines (PBAC) Review
- Independent Review (PBS)
- Independent Review of the Impact of PBS Cost Recovery
- Streamlined Authorities (PDF 153KB)
- Review of Post PBAC Processes Report (2004)
